Gabapentin Safety in Patients With Asthma
Gabapentin is not specifically contraindicated in asthma. (dailymed.nlm.nih.gov) However, gabapentin is associated with serious breathing problems in patients with respiratory risk factors, particularly when combined with other central nervous system (CNS) depressants or when taken in the setting of underlying respiratory impairment. (fda.gov) Asthma commonly represents a “lung condition,” so risk assessment and monitoring are recommended when gabapentin is prescribed. (fda.gov)
Core Safety Recommendation
Serious respiratory depression should be treated as an important risk with gabapentin. (fda.gov) Gabapentin should be used with caution in patients with respiratory risk factors and should be avoided with other drug combinations that increase risk when clinically feasible. (fda.gov)
Medication Risk Factors Relevant to Asthma
Respiratory depression risk is increased when gabapentin is used with other CNS depressants, including opioids. (fda.gov) Respiratory depression risk is increased in the setting of underlying respiratory impairment. (fda.gov) Older age is identified as a respiratory risk factor. (fda.gov)
Combination Therapy Considerations
Co-prescribing with opioids increases the risk of serious breathing problems. (fda.gov) Co-prescribing with other CNS depressants that cause severe sleepiness or decreased awareness increases the risk of respiratory depression. (dailymed.nlm.nih.gov) In older adults, gabapentin and related agents are listed as associated with increased risk of severe sedation-related adverse events, including respiratory depression and death, with recommendations to avoid the combination with opioids when possible. (pmc.ncbi.nlm.nih.gov)
Initiation and Monitoring Practices
When gabapentin is co-prescribed with another CNS depressant, particularly an opioid, monitoring for symptoms of respiratory depression and sedation should be implemented. (dailymed.nlm.nih.gov) Initiation at a low dose should be considered when prescribing gabapentin to patients with respiratory impairment or when co-prescribing with CNS depressants. (dailymed.nlm.nih.gov) Patients should be counseled to recognize symptoms of respiratory depression and seek medical attention immediately if symptoms occur. (dailymed.nlm.nih.gov)
Common Pitfalls to Avoid
Avoiding opioid co-prescribing when possible reduces risk of serious breathing problems associated with gabapentin. (fda.gov) Using gabapentin without accounting for underlying respiratory impairment increases risk of serious respiratory depression. (fda.gov) Starting gabapentin without considering lower starting doses in higher-risk patients increases risk of adverse respiratory outcomes. (dailymed.nlm.nih.gov)
Target Outcome for Safe Use
The primary safety goal is prevention of respiratory depression through avoidance of high-risk combinations, low-dose initiation in higher-risk patients, and active monitoring for sedation and breathing difficulty. (dailymed.nlm.nih.gov)